BioSpace News Archive

Sio Gene Therapies Inc. announced that it will present new clinical and preclinical data in two oral presentations and one poster presentation at the upcoming European Society of Gene & Cell Therapy Virtual Congress 2021, to be held virtually from October 19-22, 2021.

OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that total preliminary unaudited revenue for the third quarter of 2021 was approximately $1.2 million, up from $1.1 million in the third quarter of 2020.

Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the presentation of data from the Company’s ENPP1 Deficiency Natural History Study and its gene therapy program for the treatment of ENPP1 Deficiency.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced a peer-reviewed publication in the Journal of Wound Care of an in vivo head-to-head study comparing EscharEx® and a commercial enzymatic debridement agent in the removal of chronic wound eschar.

AnPac Bio-Medical Science Co., Ltd. (Nasdaq:ANPC, “AnPac Bio,” the “Company” or “we”), announced today it has achieved a significant milestone and positive result in its general population cancer risk assessment tests and subsequent follow-up study on enrolled individuals whom obtained further check-ups and diagnosis at healthcare providers using their cancer and disease diagnostic tools.

Delix Therapeutics (the “Company”) is honored to have been named by Fierce Biotech as one of 2021’s “Fierce 15" biotechnology companies

DeepUll, a medical diagnostics company developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections, announces that it has appointed Richard Ivey as a non-executive director.

Sage Therapeutics, Inc. and Biogen Inc. announced new data from the LANDSCAPE and NEST clinical development programs evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder and postpartum depression presented at the 34th European College of Neuropsychopharmacology Congress, taking place October 2-5, 2021.

Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced details about its plan to initiate a randomized Phase 2 clinical study evaluating SRF388, a potential first-in-class antibody against IL-27, in combination with Roche’s atezolizumab and bevacizumab, in patients with treatment-naïve hepatocellular carcinoma.

First patient has been enrolled in 12-week non-alcoholic fatty liver disease (NAFLD) study